William Oliver Tobin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6291321/publications.pdf

Version: 2024-02-01

78	2,251	361296	223716
papers	citations	20 h-index	46 g-index

80	80	80	2715
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	1.7	295
2	DPPX potassium channel antibody. Neurology, 2014, 83, 1797-1803.	1.5	255
3	The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology, 2016, 87, 1393-1399.	1.5	230
4	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2017, 140, 2415-2425.	3.7	158
5	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	4.5	124
6	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clinic Proceedings, 2019, 94, 2054-2071.	1.4	116
7	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology, 2018, 125, 1628-1637.	2.5	108
8	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4â€“IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmology, 2018, 136, 419.	1.4	104
9	Immediate Effects of Thermalâ€“Tactile Stimulation on Timing of Swallow in Idiopathic Parkinsonâ€™s Disease. Dysphagia, 2010, 25, 207-215.	1.0	63
10	Longitudinally extensive transverse myelitis. Current Opinion in Neurology, 2014, 27, 279-289.	1.8	56
11	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1021-1026.	0.9	49
12	Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. Radiology, 2021, 299, 313-323.	3.6	46
13	Exploring the overlap between multiple sclerosis, tumefactive demyelination and BalÃ³â€™s concentric sclerosis. Multiple Sclerosis Journal, 2016, 22, 986-992.	1.4	44
14	Neuroradiologic manifestations of Erdheim-Chester disease. Neurology: Clinical Practice, 2018, 8, 15-20.	0.8	43
15	CLIPPERS. Current Neurology and Neuroscience Reports, 2017, 17, 65.	2.0	30
16	Identification of Stroke Mimics in the Emergency Department Setting. Journal of Brain Disease, 2009, 1, JCNSD.S2280.	0.1	25
17	Efficacy of BRAF-Inhibitor Therapy in BRAF V600E-Mutated Adult Langerhans Cell Histiocytosis. Oncologist, 2020, 25, 1001-1004.	1.9	25
18	Prevalence of ExÂVivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100Â® and VerifyNowÂ®. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e84-e92.	0.7	24

#	Article	IF	Citations
19	Efficacy of biological agents in the treatment of Erdheimâ€Chester disease. British Journal of Haematology, 2018, 183, 520-524.	1.2	24
20	Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood, 2019, 133, 1607-1610.	0.6	23
21	Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: First results from the TRinity AntiPlatelet responsiveness (TrAP) study. British Journal of Haematology, 2011, 152, 640-647.	1.2	21
22	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	2.0	21
23	Stopping immunomodulatory medications in MS: Frequency, reasons and consequences. Multiple Sclerosis and Related Disorders, 2015, 4, 437-443.	0.9	19
24	Frequent inaccuracies in ABCD2 scoring in non-stroke specialists' referrals to a daily Rapid Access Stroke Prevention service. Journal of the Neurological Sciences, 2013, 332, 30-34.	0.3	18
25	Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. Neurology, 2021, 97, e1906-e1913.	1.5	18
26	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. American Journal of Hematology, 2021, 96, 1604-1610.	2.0	18
27	Cervical Artery Dissection in Young Adults in the Stroke in Young Fabry Patients (sifap1) Study. Cerebrovascular Diseases, 2015, 39, 110-121.	0.8	17
28	Multiple sclerosis masquerading as Alzheimer-type dementia: Clinical, radiological and pathological findings. Multiple Sclerosis Journal, 2016, 22, 698-704.	1.4	17
29	Facial Myokymia and Hemifacial Spasm in Multiple Sclerosis. Neurologist, 2018, 23, 1-6.	0.4	17
30	Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment. Journal of the Neurological Sciences, 2016, 361, 13-18.	0.3	16
31	Diagnostic Yield and Safety of Cerebellar and Brainstem Parenchymal Biopsy. World Neurosurgery, 2015, 84, 1973-1976.	0.7	12
32	Clinical and Radiologic Features, Pathology, and Treatment of BalÃ³ Concentric Sclerosis. Neurology, 2021, 97, e414-e422.	1.5	12
33	<scp>Magnetic Resonance Imaging</scp> Correlates of Multiple Sclerosis Immunopathological Patterns. Annals of Neurology, 2021, 90, 440-454.	2.8	12
34	Pathological findings in central nervous system demyelination associated with infliximab. Multiple Sclerosis Journal, 2020, 26, 1124-1129.	1.4	11
35	Populationâ€based incidence and clinicoâ€radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. European Journal of Neurology, 2022, 29, 782-789.	1.7	11
36	Cyclophosphamide in treatment of tumefactive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102627.	0.9	10

#	Article	IF	Citations
37	Prevalence of bipolar disorder in multiple sclerosis: a systematic review and meta-analysis. Evidence-Based Mental Health, 2021, 24, 88-94.	2.2	10
38	Interobserver agreement in ABCD scoring between non-stroke specialists and vascular neurologists following suspected TIA is only fair. Journal of Neurology, 2011, 258, 1001-1007.	1.8	9
39	Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. Journal of the Neurological Sciences, 2017, 375, 404-410.	0.3	9
40	Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS â€“ NO. Multiple Sclerosis Journal, 2017, 23, 1190-1192.	1.4	9
41	Extracranial and Intracranial Vasculopathy With â€œMoyamoya Phenomenonâ€•in Association With Alagille Syndrome. Frontiers in Neurology, 2018, 9, 1194.	1.1	9
42	Low-dose vemurafenib monotherapy in BRAF^{V600E}-mutated Erdheim-Chester disease. Leukemia and Lymphoma, 2020, 61, 2733-2737.	0.6	9
43	Sustained, complete response to pexidartinib in a patient with <scp>CSF1R</scp>â€mutated Erdheimâ€“Chester disease. American Journal of Hematology, 2022, 97, 293-302.	2.0	9
44	Assessment of â€˜on-treatment platelet reactivityâ€™ and relationship with cerebral micro-embolic signals in asymptomatic and symptomatic carotid stenosis. Journal of the Neurological Sciences, 2017, 376, 133-139.	0.3	8
45	Neuromyelitis Optica and Herpes Simplex Virus 2. Neurologist, 2018, 23, 92-93.	0.4	8
46	Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 441-452.	1.4	8
47	Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis. Aging, 2020, 12, 15134-15156.	1.4	8
48	Clinicalâ€“radiologicalâ€“pathological spectrum of central nervous systemâ€“idiopathic inflammatory demyelinating disease in the elderly. Multiple Sclerosis Journal, 2017, 23, 1204-1213.	1.4	6
49	Population-based study of â€œno evident disease activityâ€•in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e495.	3.1	6
50	Left atrial appendage occlusion in non-valvular atrial fibrillation. Lancet, The, 2009, 374, 504-506.	6.3	4
51	Dual origin of the left vertebral artery: Extracranial MRA and CTA findings. Journal of the Neurological Sciences, 2010, 298, 150-152.	0.3	4
52	Clinical Reasoning: A 30-year-old man with headache and sleep disturbance. Neurology, 2018, 90, e1535-e1540.	1.5	4
53	Teaching NeuroImages: Optic nerve sheath meningioma presenting as gaze-evoked amaurosis. Neurology, 2018, 90, e2095-e2096.	1.5	4
54	Stroke and newspapers: inattention or neglect?. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 259-261.	0.7	3

#	Article	IF	Citations
55	Rituximab Therapy in Neuromyelitis Optica. JAMA Neurology, 2015, 72, 974.	4.5	3
56	Growing the phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) in children. Developmental Medicine and Child Neurology, 2019, 61, 391-392.	1.1	3
57	Early Diagnosis and Treatment Are Associated With Improved Outcomes in Patients With Multiple Sclerosis. Neurology, 2021, 97, 799-800.	1.5	3
58	Mimics of Erdheimâ€“Chester disease. British Journal of Haematology, 2021, , .	1.2	3
59	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	1.9	3
60	Inherited genetics of adult diffuse glioma and polygenic risk scoresâ€”a review. Neuro-Oncology Practice, 2022, 9, 259-270.	1.0	3
61	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	2.8	3
62	Herpes zoster in the T1 dermatome presenting with Horner’s syndrome, radicular weakness, and postherpetic neuralgia. International Medical Case Reports Journal, 2008, 1, 1.	0.3	2
63	Hirayama Disease Presenting as 4-Limb Paresthesia. Neurologist, 2020, 25, 187-189.	0.4	2
64	Teaching Neuro Images : Primary SjÃ¶gren syndrome presenting as isolated lesion of medulla oblongata. Neurology, 2015, 85, 204-205.	1.5	1
65	Reply: A case of CLIPPERS challenging the new diagnostic criteria. Brain, 2018, 141, e13-e13.	3.7	1
66	Reply: Two cases of CLIPPERS with increased number of perivascular CD20-positive B lymphocytes. Brain, 2018, 141, e76-e76.	3.7	1
67	Teaching NeuroImages: Brain and Skin Involvement in Erdheim-Chester Disease. Neurology, 2021, 96, e1590-e1592.	1.5	1
68	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. Blood, 2018, 132, 1112-1112.	0.6	1
69	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	0.6	1
70	The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions. Multiple Sclerosis Journal, 2022, 28, 1710-1718.	1.4	1
71	173â€...Footfalls echo in the memory. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.130-e1.	0.9	0
72	Sexual dimorphism in clinical neurologyâ€”predictors of successful lumbar puncture in an â€œexpandingâ€•population. Obesity, 2014, 22, 1747-1749.	1.5	0

#	Article	IF	Citations
73	Reply: CLIPPERS, a possible symptomatic lymphohistiocytic immune reaction. Brain, 2018, 141, e6-e6.	3.7	0
74	Reply to: â€œCrowell et al. Idiopathic Central Nervous System Inflammatory Disease in the Setting of HLA-B27 Uveitisâ€• Ocular Immunology and Inflammation, 2019, 27, 918-919.	1.0	0
75	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.. Journal of Clinical Oncology, 2021, 39, 7049-7049.	0.8	0
76	BRAF^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis.. Journal of Clinical Oncology, 2021, 39, 7050-7050.	0.8	0
77	Harry Lee Parker. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 701-719.	1.2	0
78	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. Blood, 2021, 138, 2566-2566.	0.6	0